In an experimental anti-GBM disease model in Wistar–Kyoto rats, the administration of the fusion protein human CTLA4-immunoglobulin (which binds to CD80 and CD86) [79] and the mutant CTLA4-immunoglobulin (which binds only to CD80) [80] reduced disease severity. Here, CD80 is linked to glioblastoma.